Business
Quebec Expands Public Funding for CAPVAXIVE®
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the province of Quebec has added CAPVAXIVE®, a 21-valent pneumococcal conjugate vaccine, to their publicly funded adult immunization program. This addition makes the vaccine available to eligible residents in accordance with the province's eligibility criteria, helping to increase access to pneumococcal immunization.
About this update from Merck & Company, Inc.
[{"type":"text","content":"KIRKLAND, QC, Nov. 5, 2025 /PRNewswire/ -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the province of Quebec has added CAPVAXIVE®, a 21-valent pneumococcal conjugate vaccine, to their publicly funded adult immunization program. This addition makes the vaccine available to eligible residents in accordance with the province's eligibility criteria, helping to increase access to pneumococcal immunization.","length":459,"tagName":"p"},{"type":"image","alt":"Merck Logo","displaySize":"","headline":null,"caption":"Merck Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":1280,"height":720,"url":"https://mma.prnewswire.com/media/2814415/Merck_Logo.jpg"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QD5mznRxb_u0xLgivTg3ZQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://mma.prnewswire.com/media/2814415/Merck_Logo.jpg","width":960,"height":540},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/lnsNP3qabtfM4cMH54szEA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xMzUwO2NmPXdlYnA-/https://mma.prnewswire.com/media/2814415/Merck_Logo.jpg","width":1200,"height":675}},"href":"https://mma.prnewswire.com/media/2814415/Merck_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"CAPVAXIVE® is approved by Health Canada for use in adults 18 years of age and older for active immunization for the prevention of invasive pneumococcal disease (including sepsis, meningitis, bacteremic pneumonia, pleural empyema and bacteremia) caused by Streptococcus pneumoniae serotypes (3, 6A, 6C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B). Based on surveillance data from the Public Health Agency of Canada (2019–2023 combined total), the serotypes included in CAPVAXIVE® accounted for the following percentage of invasive pneumococcal disease (IPD) cases in adults:","length":628,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"~ 65% in individuals 18–49 years of age","length":39,"tagName":"p"}]},{"val":[{"type":"text","content":"~ 74% in individuals 50-64 years of age","length":39,"tagName":"p"}]},{"val":[{"type":"text","content":"~ 80% in individuals ≥65 years of age","length":37,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":115,"olType":false},{"type":"text","content"...